DÜSSELDORF, Germany, April 11, 2024 /PRNewswire/ -- Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain.
DÜSSELDORF, Germany--(BUSINESS WIRE)--Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain. As part of a planned mid-enrollment interim analysis, the independent Data Monitoring Committee (DMC) recommended the continuation of the study and confirmed the absence of safety issues among the study participants. Based on the positive DMC review and confirmed financial commitment from its investors, the company will expand the trial to Belgium, France, and Italy. The study is continuing as planned with topline efficacy readouts and a more in-depth safety analysis expected at the conclusion in 2024. AP-325 is a small molecule drug candidate that binds and modulates the GABAA receptor thereby reducing the excitability of the respective neurons. Neuropathic pain is a chronic condition that is oftentimes associated with an imbalance in excitatory and inhibitory neuronal signals. By consistently counteracting the excessive activation of neurons, signaling can be dampened resulting in reduced levels of pain.